Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721191 | 1.00 | ALDH1A1 (0.42) | ALDH1A1FFAR4FABP4TSHRKMT2A | |
| SCHEMBL9988153 | 0.82 | BRAF (0.39) | ALDH1A1FFAR4FABP4TSHRKMT2A | |
| SCHEMBL1437448 | 0.80 | CYP2C9 (0.41) | FABP4CYP2C19 | |
| SCHEMBL878464 | 0.79 | BRAF (0.53) | ALDH1A1FFAR4FABP4TSHRKMT2A | |
| SCHEMBL16266453 | 0.78 | KDM4E (0.43) | ALDH1A1FFAR4FABP4TSHRKMT2A | |
| SCHEMBL23477917 | 0.75 | KMT2A (0.41) | ALDH1A1TSHRKMT2AKDM4EPOLB | |
| SCHEMBL10965576 | 0.75 | ALDH1A1 (0.49) | ALDH1A1TSHRKMT2AKDM4EPOLB | |
| SCHEMBL16155765 | 0.75 | GAA (0.51) | ALDH1A1TSHRKMT2AKDM4EPOLB | |
| SCHEMBL30464235 | 0.75 | FFAR4 (0.50) | ALDH1A1FFAR4FABP4TSHRKMT2A | |
| SCHEMBL1127264 | 0.75 | FFAR4 (0.50) | ALDH1A1FFAR4FABP4TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746419-B | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2023-10-24 | — | — | CN | disclosed |
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-02 | — | — | US | disclosed |
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-02 | — | — | US | disclosed |
| EP-4069692-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114746419-A | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | BRAF, RAF1, NRAS | ALDH1A1 2884/4885FFAR4 3600/4885FABP4 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.